The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human study of TAS3681, an oral androgen receptor (AR) antagonist with AR and AR splice variant (AR-SV) downregulation activity, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to abiraterone (ABI) and/or enzalutamide (ENZ) and chemotherapy (CT).
 
Johann S. De Bono
Employment - Institute of Cancer Research
Honoraria - Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bayer; BioExcel; Boehringer Ingelheim; Celgene; CellCentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen Oncology; Medivation; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Sanofi; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex
Consulting or Advisory Role - Amgen; Astellas Pharma; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; CellCentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Sanofi; Sanofi Aventis GmbH; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex
Research Funding - Amgen; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Bayer; CellCentric; Daiichi Sankyo; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sanofi Aventis GmbH; Sierra Oncology; Taiho Pharmaceutical; Vertex
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Cellcentric; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon; Janssen; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Qiagen; Qiagen; Sanofi; Sierra Oncology; Taiho Pharmaceutical; Terumo; Vertex
 
Natalie Cook
Honoraria - Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Novartis (Inst); Orion (Inst); Redx Pharma (Inst); Roche (Inst); Starpharma (Inst); Taiho Pharmaceutical (Inst); Tarveda Therapeutics (Inst); UCB (Inst)
 
Evan Y. Yu
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Bayer; Clovis Oncology; Exelixis; Janssen; Merck; Myovant Sciences; Sanofi
Research Funding - Bayer (Inst); Blue Earth Diagnostics (Inst); Daiichi Sankyo (Inst); Dendreon (Inst); Merck (Inst); Pharmacyclics (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Primo "Lucky" N. Lara
Consulting or Advisory Role - Calithera Biosciences (Inst); Janssen
Research Funding - Incyte (Inst); Janssen Biotech (Inst); Merck (Inst); Pharmacyclics (Inst); Taiho Pharmaceutical (Inst)
 
Judy S. Wang
Speakers' Bureau - AstraZeneca; Eisai
Research Funding - Acerta Pharma/AstraZeneca (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aileron Therapeutics (Inst); Artios (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); Birdie (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); CicloMed (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Evelo Therapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); Ignyta (Inst); Incyte (Inst); Jacobio (Inst); Janssen Research & Development (Inst); Jounce Therapeutics (Inst); Klus Pharma (Inst); Kymab (Inst); Lilly (Inst); Loxo (Inst); LSK BioPharma (Inst); Macrogenics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Phoenix Pharmaceuticals (Inst); Prelude Therapeutics (Inst); QiLu Pharmaceutical (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Stemline Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); TopAlliance BioSciences Inc (Inst); Vedanta Biosciences (Inst); Vigeo Therapeutics (Inst); Xencor (Inst)
 
Yoshihiko Yamasaki
Employment - Taiho Oncology
 
Ikuo Yamamiya
Employment - Taiho Pharmaceutical
 
Ping Gao
Employment - Innovatio Statistics
 
Elizabeth Martine Calleja
Employment - Taiho Oncology
 
Dana E. Rathkopf
Consulting or Advisory Role - AstraZeneca; Bayer; Genentech; Janssen; Myovant Sciences
Research Funding - AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); Ferring (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Medivation (Inst); Millennium (Inst); Novartis (Inst); Phosplatin Therapeutics (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TRACON Pharma (Inst)